Be Biopharma is looking to hire highly motivated, experienced, and innovative thinkers to join our growing team of passionate researchers to leverage B cells as a novel class of cellular medicine. This is an exciting opportunity to be part of a foundational team and help build Be Bio!
Roles and Responsibilities
Coordinate and manage financial close
Correspond with other departments to ensure proper accounting for purchases and month end accruals.
Interact with vendors and internal customers
Manage accounts payable
Prepare and post journal entries
Compile and draft financial reports for varying levels of management, incl. senior management and BOD
Serve as payroll back-up and support
Assist in documentation, refinement and monitoring of internal controls
Assist with financial and tax audits & reviews
Key contributor in supporting special projects
Qualifications and Experience
Bachelor’s degree, CPA preferred and
3+ years relevant accounting experience; pharmaceutical industry experience a plus.
Demonstrated strong interpersonal skills and effective in working collaboratively cross functionally
Excellent written and oral communication skills
Ability and willingness to drill-in to operational details
Strong analytical skills with superior attention to detail
Proficiency with accounting and reporting systems
Ability to handle ambiguity
Flexibility to work in a fast paced and dynamic work environment
Be Biopharma is developing a proprietary class of engineered B cell medicines to unleash the power of cell therapies beyond cell-cell contact-dependent killing (e.g., CAR-T cells). As the centerpiece of the body’s non-contact dependent humoral immune system, B cells offer a platform for cell therapy that can secrete large amounts of diverse molecular cargo in a physiologically-regulated manner. Based on discoveries by David Rawlings, MD (Chief of Immunology, Seattle Children’s and U Washington) and Richard James, PhD (Assoc Prof of Pediatrics, Seattle Children’s and U Washington), Be Biopharma is developing a pipeline of engineered B cell medicines that can restore lost signaling, regulate disease-causing pathways, and promote defense. The company will aim to demonstrate rapid proof-of-concept in genetically-defined monogenic disease, in parallel expanding to a broader set of applications across immune disease and oncology. Be Biopharma was founded in 2020 and is supported by a syndicate of leading biotech investors.